Christophe Willekens

11PUBLICATIONS
65CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Medical virologyHaematological tumoursMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Aug 11, 2026
Real-world patterns of treatment intensity and prognostic model performance in older acute myeloid leukemia: insights from the French ALFA-PPP Cohort.

|Jun 24, 2025
Comparison of induction with arsenic trioxide or chemotherapy in a real-world cohort of patients with high-risk acute promyelocytic leukemia.

Delphine Lebon, Audrey Da Rocha, Bruno Cassinat

|Apr 17, 2025
Reduced venetoclax exposure to 7 days vs standard exposure with hypomethylating agents in newly diagnosed AML patients.

Christophe Willekens, Alexandre Bazinet, Samy Chraibi

|Dec 06, 2024
Venetoclax-proteasome inhibitor-dexamethasone for unfit patients with blastic plasmacytoid dendritic cell neoplasm.

Sabine Khalife-Hachem, Arnaud Pages, Elie Akoury

|Aug 21, 2023
When monoclonal gammopathy-associated chronic neutrophilic leukemia is a reactive process distinct from a clonal myeloproliferative neoplasm: Lessons from mistakes.

Christophe Willekens, Claude Chahine, Matteo Dragani

|Apr 26, 2023
SRSF2-P95H decreases JAK/STAT signaling in hematopoietic cells and delays myelofibrosis development in mice.

Christophe Willekens, Lucie Laplane, Tracy Dagher

Pageof 2

Frequent Collaborators

3 joint publications

Stephane De Botton

2 joint publications

Delphine Lebon

2 joint publications

Emmanuel Raffoux

2 joint publications

Nicolas Duployez